Strike 3: Vi­cal ax­es its on­ly re­main­ing clin­i­cal pro­gram, com­plet­ing a tri­fec­ta of dis­as­ters

Vi­cal is once again turn­ing to the on­ly tool it ev­i­dent­ly knows how to use ex­pert­ly: the bud­get ax.

Fol­low­ing back-to-back clin­i­cal fail­ures lead­ing up to the sum­mer of 2018, Vi­cal says it has now de­cid­ed to shelve a Phase II study of the an­ti­fun­gal VL‑2397, cit­ing its de­sire to con­serve cash as it plays out its strate­gic re­view. There ev­i­dent­ly was al­so a prob­lem with re­cruit­ment for the Phase II, ac­cord­ing to the biotech.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.